- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Not So Different: Kathy Oubre on the Benefits of Using Biosimilars in a Community Oncology Practice
Kathy Oubre, MS, chief operating officer at the Pontchartrain Cancer Center in Louisiana, discusses the value of biosimilars.
On October 28, the Community Oncology Alliance (COA) hosted a summit on oncology payment reform which featured a panel entitled “Biosimilar Opportunities, Challenges, and Realities.” Panelist Kathy Oubre, MS, chief operating officer at the Pontchartrain Cancer Center in Louisiana and member of the board of directors for COA, discussed some of the current challenges and barriers to uptake for biosimilars. Excerpts from that panel discussion are included here.
To learn more about the COA's virtual Payer Exchange Summit on Oncology Payment Reform, click here.
To learn more about Pontchartrain Cancer Center, click here.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
